NKGen Biotech receives U.S. FDA FTD for troculeucel

NKGen Biotech (NKGN) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD, for the investigation of troculeucel, ex vivo expanded autologous NK cell therapy, for the treatment of moderate Alzheimer’s disease. FDA Fast Track designation is intended to accelerate the development and review process for therapies addressing serious health conditions and unmet medical needs and offers hope for faster access to promising new treatments.